Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Quick Read RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus…
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
Quick Read Merck’s Keytruda posted $8 billion in Q1 sales, while Summit’s ivonescimab faces binary risk ahead of…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…
NZ dad Jack Davis beats the odds after terminal cacner diagnosis
When the Weekly first shared Jack Davis’ story in 2017, the Tākaka father-of-four was fighting for his life.…
Moderna mRNA-based drug cut the risk of recurrence or death when combined with immunotherapy Keytruda
“Today’s results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination,” Kyle Holen,…
Merck’s Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning…